Ramucirumab is a targeted therapy that has been approved by the FDA for the treatment of advanced hepatocellular carcinoma (HCC), which is the most common form of liver cancer. It works by inhibiting the growth of blood vessels that supply the tumor, thus slowing its growth. Ramucirumab is used in combination with another drug called paclitaxel for patients with Hepatocellular Carcinoma Drugs who have been previously treated with sorafenib, the standard first-line therapy. In clinical trials, this combination has been shown to improve overall survival rates for patients with advanced HCC compared to placebo.
Common side effects of ramucirumab include fatigue, high blood pressure, decreased appetite, and gastrointestinal symptoms such as diarrhea and nausea. More serious side effects may include liver toxicity, bleeding, and cardiovascular events. As with any medication, it is important for patients to understand the potential benefits and risks of ramucirumab therapy and to work closely with their healthcare provider to manage side effects. With proper monitoring and management, ramucirumab can be a valuable addition to the arsenal of Hepatocellular Carcinoma Drugs therapy for patients who have been previously treated with sorafenib.
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian